HOME | PMECK | LOGIN
Publications
연세대학교 약리학교실 임상약리분과

HOME > Publications

Publications (recent 5 years)
1 S. B. Jang, Y. J. Lee, L. A. Lim, K. M. Park, B. J. Kwon, J. S. Woo, Y. I. Kim, M. S. Park, K. H. Kim, K. Park, Pharmacokinetic Comparison of Controlled-Release and Immediate-Release Oral Formulations of Simvastatin in Healthy Korean Subjects: A Randomized, Open-label, Parallel-Group, Single- and Multiple-Dose Study. Clin Ther. 2010 Jan;32(1):206-16.
2 D. W. Han, K. Park S. B. Jang, S. E. Kern, Modeling the Effect of Sevoflurane on corrected QT Prolongation: A Pharmacodynamic Analysis. Anesthesiology 2010 Oct;113(4):806-11.
3 S. J. Shin, H. C. Jeung, J. B. Ahn, S. Y. Rha, J. K. Roh, K. Park, D. H. Kim, C. Kim, H. C. Chung, A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Invest New Drugs 28(5): 650-58 (2010)
4 J. Y. Chung, S. B. Jang, Y. J. Lee, M. S. Park, K. Park, Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 51(1): 53-59 (January 2011)
5 S. K. Cho, J. S. Yoon, M. G. Lee, D. H. Lee, L. A. Lim, K. Park, M. S. Park, J. Y. Chung, Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin. Pharmacol. Ther. 89(3): 416-20 (March 2011)
6 S. Hong, B. C. Cho, H. J. Choi, M. Jung, S. H. Lee, K. Park, S. K. Kim, J. H. Kim. Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients. Oncology 79(4): 293-300 (March 2011)
7 M. J. Lee, M. J. Kim, C. S. Yoon, S. Y. Song, K. Park, W. S. Kim. The T2-Shortening Effect of Gadolinium and the Optimal Conditions for Maximizing the CNR for Evaluating the Biliary System: a Phantom Study, Korean Journal of Radiology 12(3): 358-364 (May 2011)
8 S. B. Jang, Y. J. Lee, M. S. Park, Y. G. Song, J. H. Kim, H. K. Kim, B. S. Ahn, K. Park. Population pharmacokinetics of amikacin in Korean inpatients undergoing TDM. Int J Clin Pharmacol Ther 2011 June;49(6): 371-381
9 D. Lee, L. A. Lim, S. B. Jang, Y. J. Lee, J. Y. Chung, J. R. Choi, K. Kim, J. W. Park, H. Yoon, J. Lee, M. S. Park, K. Park. Pharmacokinetic Comparison of Sustained- and Immediate-Release Oral Formulations of Cilostazol in Healthy Korean Subjects: A Randomized, Open-Label, 3-Part, Sequential, 2-Period, Crossover, Single-Dose, Food-Effect, and Multiple-Dose Study, Clin Ther 33(12): 2038-2053 (December 2011).
10 S. J. Shin, J. B. Ahn, K. Park, Y. J. Lee, Y. S. Hong, T. W. Kim, H. R. Kim, S. Y. Rha, J. K. Roh, D. H. Kim, C. Kim, H. C. Chung. A Phase 1b pharmacokinetic study of the antiangiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who professed on irinotecan-based chemotherapy. Invest New Drugs 30(2): 672-80 (April 2012)
11 S. H. Chu, S. H. Jeong, E. J. Kim, M. S. Park, K. Park, M. Nam, J. Y. Shim, Y. R. Yoon. The views of patients and healthy volunteers on participation in clinical trials: An exploratory survey study. Contemporary Clinical Trials 33(4): 611-619 (July 2012)
12 S. K. Cho, E. S. Oh, K. Park, M. S. Park, J. Y. Chung. The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenet Genomics 22(8): 598-605 (August 2012).
13 E. S. Oh, S. H. Lee, M. S. Park, K. Park, J. Y. Chung. Modeling of the LDL cholesterol-lowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers. Int J Clin Pharmacol Ther 50(9):657-56 (September 2012)
14 H. Roh, H. Son, D. Lee, K. J. Yeon, H. S. Kim, K. Park. Pharmacokinetic Comparison of an Orally Disintegrating Film Formulation with a Film Coated Tablet Formulation of Sildenafil in Healthy Korean Subjects: A Randomized, Open-Label, 2-Period, Cross-Over, and Single-Dose Study. Clin Ther. 2013 Mar;35(3): 205-14
15 H. Son, H. Roh, D. Lee, H. Chang, J. Kim, C. Yun, K. Park. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Clin Ther. 2013 Jul;35(7): 915-22
16 Y. Kim, M. Son, D. Lee, H. Roh, H. Son, D. Chae, M. Y. Bahng, K. Park. Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Clin Ther. 2013 Jul;35(7): 934-40
17 H. Son, D. Lee, L. A. Lim, S. B. Jang, H. Roh, K. Park. Development of a pharmacokinetic interaction model for Co-administration of simvastatin and amlodipine. Drug Metab Pharmacokinet. 29(2): 120-128 (April 2014)
18 D. Lee, H. Son, L. A. Lim, K. Park. Population pharmacokinetic analysis of diurnal and seasonal variations of plasma concentrations of cilostazol in healthy volunteers. Ther Drug Monit. (in press)
19 D. Lee, H. Roh, H. Son, S. B. Jang, S. Lee, S. Y. Nam, K. Park. Pharmacokinetic Interaction between Rosuvastatin and Metformin: A Randomized, Open-Label, 3-Period, Crossover, Multiple-Dose Study in Healthy Korean Male Volunteers. Clin Ther (in press)
20 M. Son, Y. Kim, D. Lee, H. Roh, H. Son, J. Guk, S. B. Jang, S. Y. Nam, K. Park. Pharmacokinetic Interaction between Rosuvastatin and Telmisartan in Healthy Korean Male Volunteers: A Randomized, Open-label, 2-Period, Crossover, Multiple-dose Study/ Clin Ther (in press).
21 H. Roh, H. Son, D. Lee, H. Chang, C. Yun, H. Chang, C. Yun, K. Park. Pharmacokinetic Interaction between Rosuvastatin and Olmesartan: A Randomized, Open-Label, 3-Period, Cross-Over, and Multiple-Dose Study in Healthy Korean Male Subjects. Clin Ther (in press)